CN109757100A - 用于向中枢神经系统（cns）递送蛋白质的工程改造的寄生虫 - Google Patents

用于向中枢神经系统（cns）递送蛋白质的工程改造的寄生虫 Download PDF

Info

Publication number
CN109757100A
CN109757100A CN201780053576.6A CN201780053576A CN109757100A CN 109757100 A CN109757100 A CN 109757100A CN 201780053576 A CN201780053576 A CN 201780053576A CN 109757100 A CN109757100 A CN 109757100A
Authority
CN
China
Prior art keywords
protein
toxoplasma gondii
nucleic acid
toxoplasma
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780053576.6A
Other languages
English (en)
Chinese (zh)
Inventor
O.瑞沙维
S.布拉莎
L.舍因内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Ramot at Tel Aviv University Ltd
Original Assignee
University of Glasgow
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, Ramot at Tel Aviv University Ltd filed Critical University of Glasgow
Publication of CN109757100A publication Critical patent/CN109757100A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01015—Aspartoacylase (3.5.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/05—Carbon-nitrogen ligases with glutamine as amido-N-donor (6.3.5)
    • C12Y603/05005—Carbamoyl-phosphate synthase (glutamine-hydrolysing) (6.3.5.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780053576.6A 2016-06-29 2017-06-29 用于向中枢神经系统（cns）递送蛋白质的工程改造的寄生虫 Pending CN109757100A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355898P 2016-06-29 2016-06-29
US62/355898 2016-06-29
PCT/IL2017/050731 WO2018002938A1 (en) 2016-06-29 2017-06-29 Engineered parasites for delivering protein to the central nervous system (cns)

Publications (1)

Publication Number Publication Date
CN109757100A true CN109757100A (zh) 2019-05-14

Family

ID=60786743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053576.6A Pending CN109757100A (zh) 2016-06-29 2017-06-29 用于向中枢神经系统（cns）递送蛋白质的工程改造的寄生虫

Country Status (8)

Country Link
US (3) US11260081B2 (enExample)
EP (1) EP3478301A4 (enExample)
JP (3) JP7148415B2 (enExample)
KR (1) KR102513120B1 (enExample)
CN (1) CN109757100A (enExample)
AU (1) AU2017289886A1 (enExample)
CA (1) CA3028334A1 (enExample)
WO (1) WO2018002938A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119925428A (zh) * 2025-04-07 2025-05-06 天津捷昂康生物科技发展有限公司 一种树突状细胞在预防和/或治疗脱髓鞘疾病中的应用
CN120424771A (zh) * 2025-07-08 2025-08-05 华中农业大学 弓形虫mic19基因敲除虫株及其构建方法与应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7148415B2 (ja) * 2016-06-29 2022-10-05 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫
BR112020021903A2 (pt) 2018-04-27 2021-03-02 Rocket Pharmaceuticals, Ltd. terapia genética para degeneração do snc
CN109369796A (zh) * 2018-09-27 2019-02-22 华中农业大学 一种检测羊弓形虫IgG抗体的酶联免疫方法
CN110117609B (zh) * 2019-05-20 2023-06-02 安徽农业大学 一种真菌基因敲除双荧光筛选方法
EP3976071A1 (en) * 2019-05-29 2022-04-06 Université de Tours Toxoplasma platform for treating cancer
EP3980059A1 (en) * 2019-06-10 2022-04-13 Infectious Disease Research Institute Methods and compositions of astrovirus replicons
CN115379834A (zh) 2020-03-11 2022-11-22 马萨诸塞眼科耳科诊所 用于nmnat1相关视网膜变性的基因疗法
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses
KR102561980B1 (ko) * 2021-03-16 2023-08-01 한양대학교 에리카산학협력단 톡소포자충 gra9 단백질 또는 상기 단백질을 암호화하는 유전자를 유효성분으로 포함하는, 염증성 질환 예방 또는 치료용 약학적 조성물
CN114524869B (zh) * 2022-01-25 2023-06-09 华中农业大学 弓形虫微线体蛋白MIC17a及其应用
KR102834734B1 (ko) * 2022-04-28 2025-07-16 경희대학교 산학협력단 톡소포자충의 항원 rop4를 포함하는 재조합 백시니아 바이러스 백신
WO2024064918A2 (en) * 2022-09-23 2024-03-28 Novome Biotechnologies, Inc. Recombinant fusion polypeptides for secreting soluble, heterologous cargo
WO2025026988A1 (en) * 2023-07-28 2025-02-06 Theranexus Mutated tfeb for treating lysosomal disorders
EP4560316A1 (en) * 2023-11-23 2025-05-28 Biokit Research & Development S.L.U. Antigenic regions for the detection of anti-toxoplasma gondii igm antibodies
CN117925759B (zh) * 2024-01-23 2024-07-02 通化康元生物科技有限公司 林蛙多肽制剂及其在食品和化妆品中的应用
WO2025235741A1 (en) * 2024-05-09 2025-11-13 Grann Pharmaceuticals Inc. Compositions and methods for modulating mecp2 activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244437A1 (en) * 2002-09-20 2005-11-03 Van Poppel Nicole Francisca J Live antenuated parasite vaccine
WO2016046321A1 (en) * 2014-09-25 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cancer and infectious diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693325A (en) * 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US8293224B2 (en) 2000-02-07 2012-10-23 Trustees Of Dartmouth College Attenuated uracil auxotroph of an apicomplexan and use thereof
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US9757440B2 (en) 2007-10-29 2017-09-12 Trustees Of Dartmouth College Method for treating cancer with Toxoplasma gondii vaccine
JP7148415B2 (ja) 2016-06-29 2022-10-05 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド タンパク質を中枢神経系（ｃｎｓ）に送達するための、組換え寄生虫

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244437A1 (en) * 2002-09-20 2005-11-03 Van Poppel Nicole Francisca J Live antenuated parasite vaccine
WO2016046321A1 (en) * 2014-09-25 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cancer and infectious diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANITA A. KOSHY ET AL.: "Toxoplasma secreting Cre recombinase for analysis of host-parasite interactions", 《NAT METHODS.》 *
CORINNE MERCIER ET AL.: "Toxoplasma secretory granules: one population or more?", 《TRENDS IN PARASITOLOGY》 *
胡玲英等: "弓形虫致密颗粒蛋白的生物学功能及免疫原性研究的新进展", 《中国人兽共患病学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119925428A (zh) * 2025-04-07 2025-05-06 天津捷昂康生物科技发展有限公司 一种树突状细胞在预防和/或治疗脱髓鞘疾病中的应用
CN119925428B (zh) * 2025-04-07 2025-07-11 天津捷昂康生物科技发展有限公司 一种树突状细胞在预防和/或治疗脱髓鞘疾病中的应用
CN120424771A (zh) * 2025-07-08 2025-08-05 华中农业大学 弓形虫mic19基因敲除虫株及其构建方法与应用

Also Published As

Publication number Publication date
US20220160790A1 (en) 2022-05-26
EP3478301A1 (en) 2019-05-08
AU2017289886A1 (en) 2019-01-24
CA3028334A1 (en) 2018-01-04
US20200121731A1 (en) 2020-04-23
JP2019525744A (ja) 2019-09-12
KR20190021339A (ko) 2019-03-05
US11260081B2 (en) 2022-03-01
EP3478301A4 (en) 2020-04-22
JP7748681B2 (ja) 2025-10-03
JP2022184996A (ja) 2022-12-13
WO2018002938A1 (en) 2018-01-04
US12070476B2 (en) 2024-08-27
JP7497397B2 (ja) 2024-06-10
JP7148415B2 (ja) 2022-10-05
JP2024112982A (ja) 2024-08-21
US20250057892A1 (en) 2025-02-20
KR102513120B1 (ko) 2023-03-27

Similar Documents

Publication Publication Date Title
CN109757100A (zh) 用于向中枢神经系统（cns）递送蛋白质的工程改造的寄生虫
US20240269169A1 (en) Compositions and methods for treating diseases and disorders of the central nervous system
HU229805B1 (en) Photochemical internalization for delivery of molecules into the cytosol
US20060247195A1 (en) Method of altering cell properties by administering rna
JP2020186256A (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
NZ787373A (en) Novel crispr enzymes and systems
CN109312308A (zh) 通过使用核酸酶来进行人神经干细胞的基因组编辑
UA126549C2 (uk) Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
CN109476716A (zh) 治疗线粒体障碍的方法
JP2010209074A5 (enExample)
JPH04504125A (ja) 脊椎動物における外因性ポリヌクレオチド配列の発現
CN107115352A (zh) 微rna和包含微rna的组合物
CN102083975A (zh) 小环dna载体制剂及其制备方法和使用方法
UA128281C2 (uk) Одержання маїсу, стійкого до північної плямистості листя
CN108137659A (zh) 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的用于预防和治疗中枢神经系统疾病的药物组合物
US20230392126A1 (en) Tissue organoids
KR102289661B1 (ko) 요산분해효소를 과발현하는 줄기세포를 유효성분으로 포함하는 통풍의 예방 또는 치료용 조성물
KR20250020536A (ko) 타우 단백질 집적 억제용 조성물 및 집적억제 방법
WO2011077143A1 (en) Transformation of commensal neisseria
Uzzaman et al. Embryonic stem cell–derived astrocytes: a novel gene therapy vector for brain tumors
EP3966329A1 (en) Methods and compositions using auxotrophic regulatable cells
KR102806545B1 (ko) 활성 산소종에 의해 손상된 미토콘드리아의 선택적 제거용 분자 스위치 및 이의 용도
CN116437942A (zh) 包含manf的用于预防或治疗神经精神性疾病的组合物
EP3937968A1 (en) Transgenic probiotic e. coli cell
CN112680390A (zh) 重组微生物、其代谢物、及其用于治疗或/及预防脂肪肝及心血管疾病的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190514